Display options
Cite
Filipovic L, Arandelovic S, Gligorijevic N, et al. Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin. Radiol Oncol. 2013;47(4):346-57doi: 10.2478/raon-2013-0050.
Filipovic, L., Arandelovic, S., Gligorijevic, N., Krivokuca, A., Jankovic, R., Srdic-Rajic, T., Rakic, G., Tesic, Z., & Radulovic, S. (2013). Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin. Radiology and oncology, 47(4), 346-57. https://doi.org/10.2478/raon-2013-0050
Filipovic, Lana, et al. "Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin." Radiology and oncology vol. 47,4 (2013): 346-57. doi: https://doi.org/10.2478/raon-2013-0050
Filipovic L, Arandelovic S, Gligorijevic N, Krivokuca A, Jankovic R, Srdic-Rajic T, Rakic G, Tesic Z, Radulovic S. Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin. Radiol Oncol. 2013 Oct 08;47(4):346-57. doi: 10.2478/raon-2013-0050. eCollection 2013. PMID: 24294179; PMCID: PMC3814279.
Copy Download .nbib Format: NLM
Share it on

Radiol Oncol. 2013 Oct 08;47(4):346-57. doi: 10.2478/raon-2013-0050. eCollection 2013.

Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.

Radiology and oncology

Lana Filipovic, Sandra Arandelovic, Nevenka Gligorijevic, Ana Krivokuca, Radmila Jankovic, Tatjana Srdic-Rajic, Gordana Rakic, Zivoslav Tesic, Sinisa Radulovic

Affiliations

  1. Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

PMID: 24294179 PMCID: PMC3814279 DOI: 10.2478/raon-2013-0050

Abstract

BACKGROUND: In our previous study we reported the synthesis and cytotoxicity of two trans-platinum(II) complexes: trans-[PtCl2(3-acetylpyridine)2] (1) and trans-[PtCl2(4-acetylpyridine)2] (2), revealing significant cytotoxic potential of 2. In order to evaluate the mechanism underlying biological activity of both trans-Pt(II) isomers, comparative studies versus cisplatin were performed in HeLa, MRC-5 and MS1 cells.

MATERIALS AND METHODS: The cytotoxic activity of the investigated complexes was determined using SRB assay. The colagenolytic activity was determined using gelatin zymography, while the effect of platinum complexes on matrix metalloproteinases 2 and 9 mRNA expression was evaluated by quantitative real-time PCR. Apoptotic potential and cell cycle alterations were determined by FACS analyses. Western blot analysis was used to evaluate the effect on expression of DNA-repair enzyme ERCC1, and quantitative real-time PCR was used for the ERCC1 mRNA expression analysis. In vitro antiangiogenic potential was determined by tube formation assay. Platinum content in intracellular DNA and proteins was determined by inductively coupled plasma-optical emission spectrometry.

RESULTS: Compound 2 displayed an apparent cytoselective profile, and flow cytometry analysis in HeLa cells indicated that 2 exerted antiproliferative effect through apoptosis induction, while 1 induced both apoptosis and necrosis. Action of 1 and 2, as analyzed by quantitative real-time PCR and Western blot, was associated with down-regulation of ERCC1. Both trans-complexes inhibited MMP-9 mRNA expression in HeLa, while 2 significantly abrogated in vitro tubulogenesis in MS1 cells.

CONCLUSIONS: The ability of 2 to induce multiple and selective in vitro cytotoxic effects encourages further investigations of trans-platinum(II) complexes with substituted pyridines.

Keywords: MMPs; MRC-5; angiogenesis; apoptosis; trans-platinum(II)

References

  1. J Biol Chem. 2001 Oct 19;276(42):38781-6 - PubMed
  2. J Med Chem. 2000 Jun 15;43(12):2411-8 - PubMed
  3. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  4. J Inorg Biochem. 2012 Sep;114:106-12 - PubMed
  5. Crit Rev Oncol Hematol. 2002 Jun;42(3):317-25 - PubMed
  6. Anticancer Agents Med Chem. 2010 Jun;10(5):396-411 - PubMed
  7. Biochemistry. 2003 May 27;42(20):6321-32 - PubMed
  8. ChemMedChem. 2011 Jul 4;6(7):1283-90 - PubMed
  9. Clin Cancer Res. 2005 Sep 1;11(17):6100-2 - PubMed
  10. Eur J Med Chem. 2011 Oct;46(10):4957-63 - PubMed
  11. Chembiochem. 2005 Jul;6(7):1157-66 - PubMed
  12. Cell Biochem Funct. 2003 Dec;21(4):381-6 - PubMed
  13. Cancer Res. 1992 Sep 15;52(18):5065-72 - PubMed
  14. Cancer Res. 1996 Feb 1;56(3):556-62 - PubMed
  15. J Med Chem. 1993 Feb 19;36(4):510-2 - PubMed
  16. Biotechniques. 2005 Jan;38(1):73-83 - PubMed
  17. Mol Cancer. 2011 Mar 08;10:24 - PubMed
  18. Dalton Trans. 2009 May 14;(18):3457-66 - PubMed
  19. J Inorg Biochem. 2004 Aug;98(8):1261-70 - PubMed
  20. Metallomics. 2009;1(4):280-91 - PubMed
  21. Vasc Cell. 2011 Feb 14;3(1):6 - PubMed
  22. Curr Cancer Drug Targets. 2003 Feb;3(1):21-9 - PubMed
  23. J Med Chem. 2006 Apr 20;49(8):2640-51 - PubMed
  24. J Inorg Biochem. 2011 Mar;105(3):400-9 - PubMed
  25. J Exp Clin Cancer Res. 2002 Dec;21(4):519-26 - PubMed
  26. J Inorg Biochem. 2012 Mar;108:53-61 - PubMed
  27. Nat Rev Cancer. 2007 Aug;7(8):573-84 - PubMed
  28. Nature. 1970 Jul 11;227(5254):168-70 - PubMed
  29. Anticancer Res. 2010 Jul;30(7):2531-8 - PubMed
  30. Eur J Inorg Chem. 2009 Apr 1;2009(10):1293 - PubMed
  31. Chembiochem. 2009 Jan 5;10(1):73-4 - PubMed
  32. Br J Pharmacol. 2010 Jul;160(6):1362-77 - PubMed
  33. J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 - PubMed
  34. Eur J Med Chem. 2009 May;44(5):1921-5 - PubMed
  35. Curr Med Chem. 2002 Sep;9(17):1611-8 - PubMed
  36. Eur J Med Chem. 2010 Jan;45(1):134-41 - PubMed
  37. J Med Chem. 2007 Jul 26;50(15):3434-41 - PubMed
  38. J Inorg Biochem. 2012 Nov;116:1-10 - PubMed
  39. Int J Mol Med. 2004 Dec;14(6):959-70 - PubMed
  40. Cell Physiol Biochem. 2009;23(4-6):441-8 - PubMed
  41. Inorg Chem. 2000 May 1;39(9):1882-90 - PubMed

Publication Types